Tags

Type your tag names separated by a space and hit enter

Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty: A Cohort Study.
Ann Intern Med 2019; 170(12):825-836AIM

Abstract

Background

Patients with rheumatoid arthritis (RA) are at increased risk for infection after arthroplasty, yet risks of specific biologic medications are unknown.

Objective

To compare risk for postoperative infection among biologics and to evaluate the risk associated with glucocorticoids.

Design

Retrospective cohort study.

Setting

Medicare and Truven MarketScan administrative data from January 2006 through September 2015.

Patients

Adults with RA who were having elective inpatient total knee or hip arthroplasty, either primary or revision, and had a recent infusion of or prescription for abatacept, adalimumab, etanercept, infliximab, rituximab, or tocilizumab before surgery.

Measurements

Propensity-adjusted analyses using inverse probability weights evaluated comparative risks for hospitalized infection within 30 days and prosthetic joint infection (PJI) within 1 year after surgery between biologics or with different dosages of glucocorticoids. Secondary analyses evaluated non-urinary tract hospitalized infections and 30-day readmissions.

Results

Among 9911 patients treated with biologics, 10 923 surgical procedures were identified. Outcomes were similar in patients who received different biologics. Compared with an 8.16% risk for hospitalized infection with abatacept, predicted risk from propensity-weighted models ranged from 6.87% (95% CI, 5.30% to 8.90%) with adalimumab to 8.90% (CI, 5.70% to 13.52%) with rituximab. Compared with a 2.14% 1-year cumulative incidence of PJI with abatacept, predicted incidence ranged from 0.35% (CI, 0.11% to 1.12%) with rituximab to 3.67% (CI, 1.69% to 7.88%) with tocilizumab. Glucocorticoids were associated with a dose-dependent increase in postoperative risk for all outcomes. Propensity-weighted models showed that use of more than 10 mg of glucocorticoids per day (vs. no glucocorticoid use) resulted in a predicted risk for hospitalized infection of 13.25% (CI, 9.72% to 17.81%) (vs. 6.78%) and a predicted 1-year cumulative incidence of PJI of 3.83% (CI, 2.13% to 6.87%) (vs. 2.09%).

Limitation

Residual confounding is possible, and sample sizes for rituximab and tocilizumab were small.

Conclusion

Risks for hospitalized infection, PJI, and readmission after arthroplasty were similar across biologics. In contrast, glucocorticoid use, especially with dosages above 10 mg/d, was associated with greater risk for adverse outcomes.

Primary Funding Source

Rheumatology Research Foundation, National Institutes of Health, and Bristol-Myers Squibb.

Authors+Show Affiliations

University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania (M.D.G., J.Y.H., Q.W.).University of Pennsylvania Perelman School of Medicine and Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania (J.F.B.).Oregon Health & Science University, Portland, Oregon (K.W.).Bristol-Myers Squibb, New York, New York (E.A., S.C., T.A.S.).University of Alabama at Birmingham, Birmingham, Alabama (L.C., F.X., S.Y., J.R.C.).Bristol-Myers Squibb, New York, New York (E.A., S.C., T.A.S.).University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania (M.D.G., J.Y.H., Q.W.).Bristol-Myers Squibb, New York, New York (E.A., S.C., T.A.S.).University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania (M.D.G., J.Y.H., Q.W.).University of Alabama at Birmingham, Birmingham, Alabama (L.C., F.X., S.Y., J.R.C.).University of Alabama at Birmingham, Birmingham, Alabama (L.C., F.X., S.Y., J.R.C.).University of Alabama at Birmingham, Birmingham, Alabama (L.C., F.X., S.Y., J.R.C.).

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31108503

Citation

George, Michael D., et al. "Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty: a Cohort Study." Annals of Internal Medicine, vol. 170, no. 12, 2019, pp. 825-836.
George MD, Baker JF, Winthrop K, et al. Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty: A Cohort Study. Ann Intern Med. 2019;170(12):825-836.
George, M. D., Baker, J. F., Winthrop, K., Alemao, E., Chen, L., Connolly, S., ... Curtis, J. R. (2019). Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty: A Cohort Study. Annals of Internal Medicine, 170(12), pp. 825-836. doi:10.7326/M18-2217.
George MD, et al. Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty: a Cohort Study. Ann Intern Med. 2019 Jun 18;170(12):825-836. PubMed PMID: 31108503.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty: A Cohort Study. AU - George,Michael D, AU - Baker,Joshua F, AU - Winthrop,Kevin, AU - Alemao,Evo, AU - Chen,Lang, AU - Connolly,Sean, AU - Hsu,Jesse Y, AU - Simon,Teresa A, AU - Wu,Qufei, AU - Xie,Fenglong, AU - Yang,Shuo, AU - Curtis,Jeffrey R, Y1 - 2019/05/21/ PY - 2019/5/21/pubmed PY - 2019/5/21/medline PY - 2019/5/21/entrez SP - 825 EP - 836 JF - Annals of internal medicine JO - Ann. Intern. Med. VL - 170 IS - 12 N2 - Background: Patients with rheumatoid arthritis (RA) are at increased risk for infection after arthroplasty, yet risks of specific biologic medications are unknown. Objective: To compare risk for postoperative infection among biologics and to evaluate the risk associated with glucocorticoids. Design: Retrospective cohort study. Setting: Medicare and Truven MarketScan administrative data from January 2006 through September 2015. Patients: Adults with RA who were having elective inpatient total knee or hip arthroplasty, either primary or revision, and had a recent infusion of or prescription for abatacept, adalimumab, etanercept, infliximab, rituximab, or tocilizumab before surgery. Measurements: Propensity-adjusted analyses using inverse probability weights evaluated comparative risks for hospitalized infection within 30 days and prosthetic joint infection (PJI) within 1 year after surgery between biologics or with different dosages of glucocorticoids. Secondary analyses evaluated non-urinary tract hospitalized infections and 30-day readmissions. Results: Among 9911 patients treated with biologics, 10 923 surgical procedures were identified. Outcomes were similar in patients who received different biologics. Compared with an 8.16% risk for hospitalized infection with abatacept, predicted risk from propensity-weighted models ranged from 6.87% (95% CI, 5.30% to 8.90%) with adalimumab to 8.90% (CI, 5.70% to 13.52%) with rituximab. Compared with a 2.14% 1-year cumulative incidence of PJI with abatacept, predicted incidence ranged from 0.35% (CI, 0.11% to 1.12%) with rituximab to 3.67% (CI, 1.69% to 7.88%) with tocilizumab. Glucocorticoids were associated with a dose-dependent increase in postoperative risk for all outcomes. Propensity-weighted models showed that use of more than 10 mg of glucocorticoids per day (vs. no glucocorticoid use) resulted in a predicted risk for hospitalized infection of 13.25% (CI, 9.72% to 17.81%) (vs. 6.78%) and a predicted 1-year cumulative incidence of PJI of 3.83% (CI, 2.13% to 6.87%) (vs. 2.09%). Limitation: Residual confounding is possible, and sample sizes for rituximab and tocilizumab were small. Conclusion: Risks for hospitalized infection, PJI, and readmission after arthroplasty were similar across biologics. In contrast, glucocorticoid use, especially with dosages above 10 mg/d, was associated with greater risk for adverse outcomes. Primary Funding Source: Rheumatology Research Foundation, National Institutes of Health, and Bristol-Myers Squibb. SN - 1539-3704 UR - https://www.unboundmedicine.com/medline/citation/31108503/Risk_of_Biologics_and_Glucocorticoids_in_Patients_With_Rheumatoid_Arthritis_Undergoing_Arthroplasty:_A_Cohort_Study L2 - https://www.annals.org/article.aspx?doi=10.7326/M18-2217 DB - PRIME DP - Unbound Medicine ER -